Skip to main content

Table 2 In 110 ANAS patients, factors associated with outcomes or relapses in univariate analysis

From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors

Outcomes

Relapses

 

Good outcomes

Poor outcomes

p

 

NO relapose

Relapses

p

Types of onset

  

0.0002

Types of onset

  

0.0163

 Acute

43(58.90%)

9(24.32%)

 

Acute

31(40.26%)

21(63.64%)

 

 Sub-acute

9(12.33%)

4(10.81%)

 

Sub-acute

9(11.69%)

4(12.12%)

 

 Chronic

21(28.77%)

24(64.86%)

 

Chronic

37(48.05%)

8(24.24%)

 

Elevated CSF PRO

  

0.0075

Elevated CSF PRO

  

0.0012

 No

42(73.68%)

11(42.31%)

 

NO

29(51.79%)

24(88.89%)

 

 Yes

15(26.32%)

15(57.69%)

 

YES

27(48.21%)

3(11.11%)

 

Tumours

  

<0.0001

MRI Flair/T2 abnormalities

  

0.0345

 No

57(81.43%)

13(18.57%)

 

NO

52(73.24%)

14(50.00%)

 

 Yes

16(40.00%)

24(60.00%)

 

YES

19(26.76%)

14(50.00%)

 

AE or PNS

  

0.0004

AE or PNS

  

0.0113

 AE

37(50.68%)

6(16.22%)

 

AE

24(55.81%)

19(44.19%)

 

 PNS

36(49.32%)

31(83.78%)

 

PNS

53(79.10%)

14(20.90%)

 

Serum CXCL10

38.02(7.84-525.63)

48.77(7.58-516.68)

0.0258

Serum CXCL10

46.73(7.58-525.63)

36.11(9.00-211.62)

0.0279

Serum BAFF

1094(440.36-5882.00)

1266.5(531.88-4173.00)

0.0409

Serum TGFβ1

41401.57(13345.38-113337.9)

64140.37(15755.87-122994.8)

0.0032

CSF leukocytosis

  

0.0606

    

 No

33(57.89%)

9(34.62%)

     

 Yes

24(42.11%)

17(65.38%)

     

CSF abnormality

  

0.0889

    

 No

25(43.86%)

6(23.08%)

     

 Yes

32(56.14%)

20(76.92%)

     
  1. Counting data are n (%), and measruement data are median (min, max)
  2. CSF cerebrospinal fluid, PRO protein, AE autoimmune encephalitis, PNS paraneoplastic neurological syndromes, CXCL C-X-C motif chemokine, BAFF B cell activating factor, MRI FLAIR Magnetic resonance imaging fluid-attenuated inversion recovery, TGFβ1 transforming growth factor β1, ANAS anti-neuron antibody syndrome